We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.42 | -0.64% | 65.09 | 65.10 | 65.22 | 65.80 | 64.89 | 65.75 | 5,571,500 | 00:26:36 |
From May 2019 to May 2024
By Allison Prang
A supplemental new drug application for a hepatitis C treatment from Gilead Sciences Inc. was approved by the U.S. Food and Drug Administration, Gilead said on Thursday.
Epclusa was approved for people who either weigh at least 17 kilograms or are at least 6 years old, Gilead said.
Gilead said the agency's approval is based on Phase II clinical trial data.
A child's dose of the treatment depends on how much they weigh and their liver's functioning, the company said.
Write to Allison Prang at allison.prang@wsj.com
(END) Dow Jones Newswires
March 19, 2020 15:33 ET (19:33 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
